Home » Pharmacology » 7-TM Receptors » Glutamate (Metabotropic) Receptors » Glutamate (Metabotropic) Group I Receptors » DMeOB

DMeOB

Cat. No. 1953

Price and Availability

For DMeOB pricing & availability please select your country from the drop down menu:
Submit

By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: [(3-Methoxyphenyl)methylene]hydrazone-3-methoxybenzaldehyde

Biological Activity

Negative allosteric modulator of the metabotropic glutamate receptor mGlu₅; displays reversible non-competitive inhibition of mGlu₅-mediated responses (IC₅₀ = 3 μM).

Technical Data

M.Wt:

268.31

Formula:

C₁₆H₁₆N₂O₂

Solubility:

Soluble to 100 mM in ethanol with gentle warming and to 100 mM in DMSO

Purity:

>98 %

Storage:

Store at RT

CAS No:

40252-74-2

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Resources

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch

Safety Data Sheet: View Safety Data Sheet

References

O'Brien et al (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 Mol.Pharmacol. 64 731. PMID: 12920211.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

Glutamate (Metabotropic) Group I Receptors

Glutamate (Metabotropic) Receptors

Keywords: DMeOB, supplier, Negative, allosteric, modulators, mGlu5, mGluR5, Group, I, Receptors, Glutamate, Metabotropic

Quick Order

Find multiple products by catalog number

Pain Research Guide

Reserve your free copy

Highlights over 280 products for Pain research. Reserve copy

mGlu Receptors Review

Written by Francine Acher, an expert in the field. Request a copy or view PDF today.

Neurobiology of Parkinson's Disease

Written by A. Schapira

'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.

7-TM Receptor Signaling

Written by T. Kenakin et al

'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy